<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>Insight数据库 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-11T20:27:43+08:00</updated>
  <subtitle>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>年销售近 20 亿！科伦药业「丙泊酚中/长链脂肪乳注射液」获批</title>
    <updated>2020-11-11T16:56:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/JM10WeXT7zG__7ekLWLi7g</id>
    <link href="https://mp.weixin.qq.com/s/JM10WeXT7zG__7ekLWLi7g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第二个 1 类新药！贝达药业「恩莎替尼」即将获批</title>
    <updated>2020-11-11T16:56:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/ufQPhQ6_cGJE7S4N_Q1yHw</id>
    <link href="https://mp.weixin.qq.com/s/ufQPhQ6_cGJE7S4N_Q1yHw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CD47 单抗信达生物领跑，国内还有这些企业在布局</title>
    <updated>2020-11-11T16:56:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/1kMOtNAgoAAc3SBCixCMPQ</id>
    <link href="https://mp.weixin.qq.com/s/1kMOtNAgoAAc3SBCixCMPQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 新医保初审结果出炉，即将开始谈判</title>
    <updated>2020-11-11T16:56:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/z2D5gFPg--4En97YsY7SPQ</id>
    <link href="https://mp.weixin.qq.com/s/z2D5gFPg--4En97YsY7SPQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>强生「达雷妥尤单抗」新适应症上市申请拟纳入优先审评</title>
    <updated>2020-11-11T16:56:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/FqYQ3y11CzO4IFAhpMMPlg</id>
    <link href="https://mp.weixin.qq.com/s/FqYQ3y11CzO4IFAhpMMPlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>半年一次！诺华长效降脂药在华启动 III 期临床，首个 PCSK9 靶向 siRNA 药物</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/C8ojDcY_Kyh6W-9rznvsdw</id>
    <link href="https://mp.weixin.qq.com/s/C8ojDcY_Kyh6W-9rznvsdw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>总额 1.39 亿美元！恒瑞 PD-L1/TGF-β 双抗授权给韩国东亚公司</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/b_SXYgLCwZLo0awmgZWAuw</id>
    <link href="https://mp.weixin.qq.com/s/b_SXYgLCwZLo0awmgZWAuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内进展最快，齐鲁制药罗米司亭启动 III 期临床</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/N_PJkCK_4BVWIK2rJEw3lg</id>
    <link href="https://mp.weixin.qq.com/s/N_PJkCK_4BVWIK2rJEw3lg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罗氏 CD3×CD20 双抗 Glofitamab 首次在华启动临床</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/4KTs0bXEO91nBEKPPNQWjQ</id>
    <link href="https://mp.weixin.qq.com/s/4KTs0bXEO91nBEKPPNQWjQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞/BioNTech 新冠疫苗有效率达 90%！国内合作伙伴复星医药涨停</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/ciG4A2h9iZBer9QFwxFf4g</id>
    <link href="https://mp.weixin.qq.com/s/ciG4A2h9iZBer9QFwxFf4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日 5 款仿制药通过一致性评价，3 个为前三家，来自信立泰、华海…</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/9LyvFfxoqW_LXC4v2vvOaA</id>
    <link href="https://mp.weixin.qq.com/s/9LyvFfxoqW_LXC4v2vvOaA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！贝达药业「恩莎替尼」审评状态变化，预计即将获批</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/5wJPGxcc9evU2wtzFw5q5g</id>
    <link href="https://mp.weixin.qq.com/s/5wJPGxcc9evU2wtzFw5q5g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>荣昌生物-B 上市首日大涨 34%，首个国产 ADC 药物即将获批</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/j_XGBLn93XeH3648ubpHyw</id>
    <link href="https://mp.weixin.qq.com/s/j_XGBLn93XeH3648ubpHyw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞 2 款新药获批临床</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/D7JGyxM2-KkTbojiXPME_w</id>
    <link href="https://mp.weixin.qq.com/s/D7JGyxM2-KkTbojiXPME_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>卫材「仑伐替尼」甲状腺癌适应症获批，2020 年即将参与医保谈判</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/9G55dqhpsBfo_yZXAEaIbA</id>
    <link href="https://mp.weixin.qq.com/s/9G55dqhpsBfo_yZXAEaIbA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>汇聚津门，三十位行业大咖论道细胞产业发展新趋势</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/Rlue4l4yVz37GZ0jm0rbBQ</id>
    <link href="https://mp.weixin.qq.com/s/Rlue4l4yVz37GZ0jm0rbBQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2 个 1 类新药已报产，荣昌生物明日港交所挂牌上市</title>
    <updated>2020-11-08T12:01:12+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/WAj5VHY9vNNzBy_7uehzWA</id>
    <link href="https://mp.weixin.qq.com/s/WAj5VHY9vNNzBy_7uehzWA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>本周 6 款注射剂过评，3 款为首家</title>
    <updated>2020-11-06T18:03:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/aYc1Ja52K5VhDm_ZhKv_wQ</id>
    <link href="https://mp.weixin.qq.com/s/aYc1Ja52K5VhDm_ZhKv_wQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百元支架时代开启！我们真要实现「支架自由」了吗？</title>
    <updated>2020-11-06T18:03:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/aciJgfQ3m8WfgegNdr6-1w</id>
    <link href="https://mp.weixin.qq.com/s/aciJgfQ3m8WfgegNdr6-1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药新股破发频频，投资逻辑生变？</title>
    <updated>2020-11-06T14:46:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/iFgOCOhGJ0gFxf_UlDHhtA</id>
    <link href="https://mp.weixin.qq.com/s/iFgOCOhGJ0gFxf_UlDHhtA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>